Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company

Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy

The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design

FDA endorses Relmada’s registrational strategy for bladder cancer therapy

GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy

GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today

Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration

EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies

The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants